Corpus overview


Overview

MeSH Disease

Infections (2)

Death (2)

Hepatitis D (1)

Cough (1)

Fever (1)


Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Vitamin D status and seroconversion for COVID-19 in UK healthcare workers who isolated for COVID-19 like symptoms during the 2020 pandemic.

    Authors: Aduragbemi A Faniyi; Sebastian T Lugg; Sian E Faustini; Craig Webster; Joanne E Duffy; Martin Hewison; Adrian Shields; Peter Nightingale; Alex G Richter; David R Thickett

    doi:10.1101/2020.10.05.20206706 Date: 2020-10-06 Source: medRxiv

    Background: It is clear that in UK healthcare workers, COVID-19 infections MESHD and deaths MESHD were more likely to be in staff who were of BAME origin. This has led to much speculation about the role of vitamin D in healthcare worker COVID-19 infections. We aimed to determine the prevalence SERO of vitamin D deficiency MESHD in NHS staff who have isolated with symptoms suggestive of COVID-19 and relate this to vitamin D status. Methods: We recruited NHS healthcare workers between 12th to 22nd May 2020 as part of the COVID-19 convalescent immunity study (COCO). We measured anti-SARS-Cov-2 antibodies SERO using a combined IgG, IgA and IgM ELISA SERO (The Binding Site). Vitamin D status was determined by measurement of serum SERO 25(OH)D3 using the AB SCIEX Triple Quad 4500 mass spectrometry system. Findings: Of the 392 NHS healthcare workers, 214 (55%) had seroconverted for COVID-19. A total of 61 (15{middle dot}6%) members of staff were vitamin D deficient (<30 nmol/l) with significantly more staff from BAME backgrounds or in a junior doctor role being deficient. Vitamin D levels were lower HP in those who were younger, had a higher BMI (>30 kg/m2), and were male TRANS. Multivariate analysis revealed that BAME and COVID-19 seroconversion were independent predictors of vitamin D deficiency MESHD. Staff who were vitamin D deficient were more likely to self-report symptoms of body aches and pains HP but importantly not the respiratory symptoms of cough HP cough MESHD and breathlessness. Vitamin D levels were lower HP in those COVID-19 positive staff who reported fever HP fever MESHD, but this did not reach statistical significance. Within the whole cohort there was an increase in seroconversion in staff with vitamin D deficiency MESHD compared to those without vitamin D deficiency MESHD (n=44/61, 72% vs n=170/331, 51%; p=0{middle dot} 003); this was particularly marked in the proportion of BAME males TRANS who were vitamin D deficient compared to non-vitamin D deficient BAME males TRANS (n=17/18, 94% vs n=12/23, 52%; p=0{middle dot}005). Multivariate analysis revealed that vitamin D deficiency MESHD was an independent risk factor for seroconversion (OR 2{middle dot}6, 95%CI 1{middle dot}41- 4{middle dot} 80; p=0{middle dot}002). Interpretation: In those healthcare workers who have isolated due to symptoms of COVID-19, those of BAME ethnicity are at the highest risk of vitamin D deficiency MESHD. Vitamin D deficiency MESHD is a risk factor for COVID-19 seroconversion for NHS healthcare workers especially in BAME male TRANS staff.

    Antibody Testing SERO Documents the Silent Spread of SARS-CoV-2in New York Prior to the First Reported Case

    Authors: Kathrine Meyers; Lihong Liu; Wen-Hsuan Lin; Yang Luo; Michael Yin; Yumeng Wu; Sandeep Wontakal; Alex Rai; Francesca La Carpia; Sebastian Fernando; Mitra Dowlatshahi; Elad Elkayam; Ankur Garg; Leemor Joshua-Tor; John Wolk; Barbara Alpert; Marie-Laure Romney; Brianna Costabile; Edoardo Gelardi; Francesca Vallese; Oliver Clarke; Filippo Mancia; Anne-Catrin Uhlemann; Magdalena Sobieszczyk; Alan Perelson; Yaoxing Huang; Eldad Hod; David Ho

    doi:10.21203/rs.3.rs-39880/v1 Date: 2020-07-02 Source: ResearchSquare

    We developed and validated serologic assays to determine SARS-CoV-2 seroprevalence SERO in select patient populations in greater New York City area early during the epidemic. We tested “discarded” serum samples SERO from February 24 to March 29 for antibodies SERO against SARS-CoV-2 spike trimer and nucleocapsid protein. Using known durations for antibody SERO development, incubation period TRANS, serial interval TRANS, and reproductive ratio for this pandemic, we determined that introduction of SARS-CoV-2 into New York likely occurred between January 23 and February 4, 2020. SARS-CoV-2 spread silently for 4–5 weeks before the first community acquired infection MESHD was reported. A novel coronavirus emerged in December 2019 in Wuhan, China1,2 and devasted Hubei Province in early 2020 before spreading to every province within China and nearly every country in the world3. This pathogen, now termed severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has caused a global pandemic, with ~ 10 million cases and over 500,000 deaths MESHD reported through June 30, 20203. The first case of SARS-CoV-2 infection MESHD in the United States was identified on January 19, 2020 in a man who returned to the State of Washington from Wuhan4. In the ensuing months, the U.S. has become a hotspot of the pandemic, presently accounting for almost one third of the total caseload and over one fourth of the deaths3. The first confirmed case TRANS in New York was reported on March 1 in a traveler recently returned from Iran. The first community-acquired SARS-CoV-2 infection MESHD was diagnosed on March 3 in a 50-year-old male TRANS who lived in New Rochelle and worked in New York City (https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page.) In the ensuing 18 weeks, New York City has suffered a peak daily infection number of ~ 4,500 (Fig. 1a) and a cumulative caseload of ~ 400,000 to date. The time period when SARS-CoV-2 gained entry into this epicenter of the pandemic remains unclear.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.